HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Drop in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 128,900 shares, a drop of 10.9% from the November 15th total of 144,700 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,020,000 shares, the days-to-cover ratio is currently 0.0 days.

HCW Biologics Stock Down 1.6 %

Shares of NASDAQ:HCWB opened at $0.35 on Tuesday. The company has a market cap of $13.24 million, a PE ratio of -0.36 and a beta of 0.88. HCW Biologics has a 52 week low of $0.28 and a 52 week high of $2.52. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.07 and a current ratio of 0.07. The firm has a 50 day simple moving average of $0.50 and a 200 day simple moving average of $0.60.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.